Glucagon analogues

• US 7,994,122 B2
• Filed: 06/16/2008
• Issued: 08/09/2011
• Est. Priority Date: 06/15/2007
• Status: Expired due to Fees

• Current Assignee: Zealand Pharma A/S
• Original Assignee: Zealand Pharma A/S
• Inventors: Meier, Eddi, Riber, Ditte, Daugaard, Jens Rosengren, Ryge, Trine Skovlund
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US12/664,534
• Publication Number:
  US 20100204105A1
• Time in Patent Office: 1,149 Days
• Field of Search: None
• US Class Current: 514/7.2
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Claims

1. A compound of the formula:

2. A compound according to claim 1 of the formula:

3. A compound according to claim 1 of the formula:

4. A nucleic acid encoding a compound according to claim 1.

5. An expression vector comprising a nucleic acid according to claim 4.

6. A host cell comprising a nucleic acid according to claim 4.

7. A pharmaceutical composition comprising a compound, according to claim 1, in admixture with pharmaceutically acceptable carrier.

8. A method of promoting weight loss, said method comprising administering a therapeutically effective amount of a compound according to claim 1 to a subject in need thereof.